We are pleased to announce that Čipčić-Bragadin Mesić & Associates one of the leading Croatian law firms advised Pfizer Inc., one of the leading pharmaceutical company, in a global business combination with Mylan N.V. The transaction involved a spin-off of Pfizer’s Upjohn business and a subsequent merger with Mylan N.V. to form a new global generics company Viatris Inc.
Viatris is forecast to have a market capitalisation of about $24 billion and will include in its portfolio blockbuster products like Pfizer’s Viagra and Mylan’s EpiPen. It is now set to overtake the largest player in the global generics market, Teva, which commands more than $18.9 billion worth of global sales, according to European Pharmaceutical Review.
We have been a part of wider legal team responsible for providing an employment law advice. The team was led by Bird & Bird and coordinated globally by PwC.
Silvije Čipčić-Bragadin, a director in Čipčić-Bragadin Mesić :
We are extremely proud to be able to advise a pharmaceutical giant like Pfizer in this complicated global transaction. As being responsible adviser in relation to Croatian market on such delicate matter like employment, which always is, made our task even more challenging. I wish to thank everyone involved; especially a team from Bird & Bird and PwC for ensuring the transaction goes smoothly and seamless. Pharmaceutical sector is very attractive at the moment and our decision to focus more over on it over the last 2 years turned to be a right one. We are now well positioned to advise the biggest companies within the sector and this transaction proves it.”
General media inquiries:
Čipčić-Bragadin Mesić and Associates law firm ltd. | Trg Republike Hrvatske 8, 10000 Zagreb, Croatia | T: +385 1 4678870 | e-mail : email@example.com